Rhizen Announces Data Presentations at ESMO 2022 for Its Clinical Stage Assets
09 Sep 2022 //
BUSINESSWIRE
Rhizen Announces First Patient Dosing in a Phase II Study of Tenalisib (RP6530)
13 Oct 2021 //
BUSINESSWIRE
Rhizen Begins Dosing in Phase II Study of Tenalisib in Breast Cancer
13 Oct 2021 //
BUSINESSWIRE
Alembic Pharma share price gains as associate company enters agreement Tenalisib
12 Oct 2020 //
MONEYCONTROL